These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28458286)

  • 1. [Development of New ADC Technology with Topoisomerase I Inhibitor].
    Agatsuma T
    Yakugaku Zasshi; 2017; 137(5):545-550. PubMed ID: 28458286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
    Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
    Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
    Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
    Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.
    Nagai Y; Oitate M; Shiozawa H; Ando O
    Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
    Iwata TN; Sugihara K; Wada T; Agatsuma T
    PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
    Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
    J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
    Andrikopoulou A; Zografos E; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
    Clin Breast Cancer; 2021 Jun; 21(3):e212-e219. PubMed ID: 32917537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.
    Conilh L; Fournet G; Fourmaux E; Murcia A; Matera EL; Joseph B; Dumontet C; Viricel W
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33803327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
    Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
    Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology.
    Ogitani Y; Abe Y; Iguchi T; Yamaguchi J; Terauchi T; Kitamura M; Goto K; Goto M; Oitate M; Yukinaga H; Yabe Y; Nakada T; Masuda T; Morita K; Agatsuma T
    Bioorg Med Chem Lett; 2016 Oct; 26(20):5069-5072. PubMed ID: 27599744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
    Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
    Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
    Nakada T; Masuda T; Naito H; Yoshida M; Ashida S; Morita K; Miyazaki H; Kasuya Y; Ogitani Y; Yamaguchi J; Abe Y; Honda T
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1542-1545. PubMed ID: 26898815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.